Abstract:
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation:本发明提供特异性结合CD154(CD40L)蛋白的结合蛋白,包括抗体,抗体衍生物和抗体片段。 本发明还提供了嵌合,人源化或完全人抗体,抗体衍生物或抗体片段,其特异性结合包含根据SEQ ID NO:1的可变重链序列的人源化Fab片段的表位,并包含可变轻链序列 根据SEQ ID NO:2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法,例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。
Abstract:
Esta invencion proporciona proteinas de union, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que especificamente se unen a la proteina CD154 (CD40L). Esta invencion tambien proporciona un anticuerpo quimerico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que especificamente se une a un epitopo al cual se une un fragmento humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 Y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteinas de union CD154 de esta invencion pueden producir una funcion efectora reducida con relacion a un segundo anticuerpo anti-CD154. Las proteinas de union CD154 de la invencion son utiles en metodos de diagnostico y terapeuticos, tales como en el tratamiento y prevencion de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que estan mediadas por las interacciones de CD154-CD40.
Abstract:
Esta invención proporciona proteínas de unión, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que específicamente se unen a la proteína CD154 (CD40L). Esta invención también proporciona un anticuerpo quimérico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que específicamente se une a un epítopo al cual se une un fragmento Fab humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteínas de unión CD154 de esta invención pueden producir una función efectora reducida con relación a un segundo anticuerpo anti-CD154. Las proteínas de unión CD154 de la invención son útiles en métodos de diagnóstico y terapéuticos, tales como en el tratamiento y prevención de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que están mediadas por las interacciones de CD154-CD40.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract:
1.- Una proteína de unión CD154 que comprende secuencias CDR1. CDR2 y CDR3 de cadena pesada seleccionadas de: (a) SEQ ID NO: 3, SEQ ID NO: 4 y SEQ ID NO: 5, respectivamente; (b) SEQ ID NO: 42, SEQ ID NO: 43 y SEQ ID NO: 44, respectivamente; y (c) SEQ ID NO: 48, SEQ ID NO: 49 y SEQ ID NO: 50, respectivamente; o que comprende secuencias CDR1, CDR2 y CDR3 de cadena liviana seleccionadas de: (a) SEQ ID NO: 6, SEQ ID NO: 7 y SEQ ID NO: 8, respectivamente; (b) SEQ ID NO: 45, SEQ ID NO: 46 y SEQ ID NO: 47, respectivamente; y (c) SEQ ID NO: 51, SEQ ID NO: 52 y SEQ ID NO: 53, respectivamente. 2.- La proteína de unión CD154 de la reivindicación 1 que comprende secuencias CDR1, CDR2 y CDR3 de cadena pesada y secuencias CDR1, CDR2 y CDR3 de cadena liviana seleccionadas de: (a) SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 y SEQ ID NO: 8, respectivamente; (b) SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46 y SEQ ID NO: 47, respectivamente; y (c) SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO. 51, SEQ ID NO: 52 y SEQ ID NO: 53, respectivamente.
Abstract:
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) p rotein. This invention also provides a chimeric, humanized or fully human an tibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy cha in sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding protein s of this invention may elicit reduced effector function relative to a secon d anti-CD154 antibody. CD154 binding proteins of this invention are useful i n diagnostic and therapeutic methods, such as in the treatment and preventio n of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.